Therapeutics News and Research

RSS

Targacept reports net loss of $15.9 million for fourth quarter 2012

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

Study demonstrates how CN2097 works to restore neural functions impaired by Angelman syndrome

In a new study in mice, a scientific collaboration centered at Brown University lays out in unprecedented detail a neurological signaling breakdown in Angelman syndrome, a disorder that affects thousands of children each year, characterized by developmental delay, seizures, and other problems.

14 Feb 2013

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

13 Feb 2013

New drug delivery system can reduce size of ovarian tumors by as much as 83%

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013

Boston College biologist receives $2.7M NIH grant to continue HIV and AIDS research

Boston College biologist Ken Williams, whose research focuses on the role of immunological cells in a range of illnesses that strike people living with HIV and AIDS, has been awarded a five-year, $2.7 million grant from the NIH's National Institute of Neurological Disorders and Stroke.

12 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Florida Hospital, Sanford-Burnham and Takeda renew research agreement

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Florida Hospital announced today that they have renewed a research agreement with Takeda Pharmaceutical Company Limited (Takeda) to extend their collaboration to discover and evaluate new therapeutic approaches to obesity. The collaboration uses a research and drug-development model that creates an early feedback loop in the discovery pipeline.

12 Feb 2013

RNF20 protein required for MLL-rearranged leukemia amplification

Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible for this cancer in order to generate potential new therapeutics.

12 Feb 2013

Unilife revenues decrease to $0.7 million for three months ended December 31, 2012

Unilife Corporation, a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2012, (the second quarter of Fiscal Year 2013).

12 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Studies to identify molecular causes and preventive and therapeutic strategies for Parkinson's

On the fourth floor of Wichita State University's McKinley Hall, biochemistry professor Kandatege Wimalasena and his group of doctoral and undergraduate students are hard at work researching Parkinson's disease (PD) - the second-most common neurodegenerative disease, affecting 1 to 2 percent of people older than 60.

7 Feb 2013

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Sangamo BioSciences, Inc. today reported fourth quarter and full year 2012 financial results and accomplishments.

7 Feb 2013

RRM1 gene may better predict survival for pancreatic adenocarcinoma

Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States.

6 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company's Phase IIa dose-escalating clinical trial for ALS.

5 Feb 2013

Study provides new insight on cancer prevention

Clear communication between cells is essential to every aspect of the body's internal function. But since cells can't talk, or send emails, how do they communicate?

4 Feb 2013

Study shows how placental circulation can influence malarial parasite behavior and infection

Malaria in pregnancy causes a range of adverse effects, including abortions, stillbirths, premature delivery and low infant birth weight. Many of these effects are thought to derive from a placental inflammatory response resulting from interaction of infected red blood cells with the placental tissue.

3 Feb 2013

Two new methods could accelerate development of improved antisense drugs

Powerful antisense drugs that target disease-associated genes to block their expression can be used to treat a broad range of diseases. Though antisense therapy has been proven effective, challenges remain in ensuring that the drugs reach their intended targets.

2 Feb 2013

Therapeutics News and Research

Targacept reports net loss of $15.9 million for fourth quarter 2012

Study demonstrates how CN2097 works to restore neural functions impaired by Angelman syndrome

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

New drug delivery system can reduce size of ovarian tumors by as much as 83%

Boston College biologist receives $2.7M NIH grant to continue HIV and AIDS research

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Florida Hospital, Sanford-Burnham and Takeda renew research agreement

RNF20 protein required for MLL-rearranged leukemia amplification

Unilife revenues decrease to $0.7 million for three months ended December 31, 2012

Sunitinib shows promise against metastatic renal cell carcinoma

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Studies to identify molecular causes and preventive and therapeutic strategies for Parkinson's

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

RRM1 gene may better predict survival for pancreatic adenocarcinoma

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

Study provides new insight on cancer prevention

Study shows how placental circulation can influence malarial parasite behavior and infection

Two new methods could accelerate development of improved antisense drugs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News